FibroGen Presents Clinical Results of Pamrevlumab Treatment in Patients with Locally Advanced Unresectable Pancreatic Cancer at ASCO 2018 Annual Meeting

SAN FRANCISCO, June 03, 2018 (GLOBE NEWSWIRE) — FibroGen, Inc. (NASDAQ:FGEN), a biopharmaceutical company, today announced Phase 1/2 clinical trial results of pamrevlumab in combination with standard-of-care chemotherapy in patients […]